Founded in 2005, Malvern Cosmeceutics Ltd stands at the forefront of innovation through its ground-breaking nanotechnology: Lipodisq®. Our cutting-edge solutions are engineered to bring about transformative changes, offering unprecedented advancements in product development and manufacturing processes. Through rigorous research and development, we have created a proprietary platform that delivers precision and efficacy in diverse applications.
We are dedicated to unlocking the full potential of Lipodisq®, advancing its applications across cosmetics, pharmaceuticals, and protein biochemistry. Our work is driven by a commitment to sustainable, ethical innovation that raises industry standards.
Lipodisq® leads the way in revolutionizing the cosmetic industry. Our Lipodisq® technology is seamlessly integrated into cosmetic formulations, offering enhanced active delivery, extended active stability, prolonged product efficacy, and a heightened user experience.
In the field of membrane protein research, Lipodisq® nanotechnology assumes a critical role in analytical processes and research applications. Lipodisq® not only enables the extraction of native membrane proteins, including GPCRs, but also stabilizes them for in-depth analytical studies. This breakthrough technology is instrumental in advancing the design of novel drug molecules and for investigating drug/receptor interaction and identifying SAR’s.
The advancement of this facet of our technology has been propelled by the growing number of academic and industrial researchers worldwide who have leveraged this technology, continually contributing to a deeper understanding of its capabilities together with an ever increasing publication list detailing the results of Lipodisq® studies.
Lipodisq® extends its applications to the nutraceutical industry. Our solutions enhance the bioavailability of nutritional active ingredients, ensuring enhanced absorption and effectiveness in nutraceutical formulations that promote health and wellness.
Lipodisq® is driving advancements in drug delivery and therapeutic solutions. Our Lipodisq® technology enables targeted drug delivery, improving treatment efficacy while minimizing side effects. We are dedicated to accelerating breakthroughs in healthcare through our innovative approach.
Founder and Managing Director, Pharmacologist, PhD polymer chemistry, an expert in developing and commercialising topical drugs and personal care products, including the development of polycationic antibacterials, for companies including Smith & Nephew. Founding member of spin-out company from Texas Tech University (USA) specialising in polycationic antibacterials for ophthalmic/pharmaceutical market. Inventor of polixetonium chloride for ophthalmic use (US 5,330,296/5,380,303) now used worldwide, products include Visene® and Refresh®. Inventor of biocompatible surface treatment for contact lenses now used in many disposable contact lens products for surface comfort enhancement.
Chemist, with over 20 years of experience in the chemical and research industries, and co-inventor of Lipodisq® technology. Serving as the lead researcher at Malvern Cosmeceutics for over two decades, he possesses extensive expertise in commercial product development, particularly utilizing Lipodisq® technology. A specialist in API and drug stabilization, formulation design, and project management, Andrew spearheads product development from conceptualisation through to market launch. With a proven track record, Andrew has overseen the successful introduction of both finished cosmetic products and raw material offerings into global markets. He has led collaborative pharmaceutical investigations involving Lipodisq® technology, including guiding projects through Innovate UK, MHRA submission and clinical appraisal.
Malvern Cosmeceutics founded and occupies premises at Malvern Hills Science Park, Worcestershire UK.
protecting Generation ɑ Lipodisq® technology submitted: “Compositions comprising a lipid and copolymer of styrene and maleic acid”.
University of Oxford, Dept Biochemistry, Prof Anthony Watts. Postgrad project work exploring the use of the Lipodisq® technology for the stabilisation and structural characterisation of membrane proteins in the liquid phase and pharmaceutical application of Lipodisq® Technology.
protecting Generation β Lipodisq® technology submitted: “Compositions comprising macromolecular assemblies of lipid and surfactant”.
1st Lipodisq® technology paper published in JACS by MCL collaborators from University of Birmingham outlining the use of P(SMA) Lipodisq® Polymers (SMALPs) for the solubilisation and stabilisation of the membrane protein PagP.
P(SMA) Lipodisq® Polymers (SMALPs) for protein and membrane laboratory research, supplying directly to academic institutions.
Curcu Nano Serum and product range containing Lipodisq® technology mark the 1st finished products for personal care market developed by Malvern Cosmeceutics in collaboration with Japanese corporation: Veritas. Veritas continues to be a key partner for Lipodisq® technology sales in Japan.
Lipodisq® Personal Care active solutions launched into the UK cosmetic industry in collaboration with UK distributor, Adina Cosmetic Ingredients. Securing supply relationships with numerous UK brands including: Nip + Fab, Organic Pharmacy, Viv-Derma, Rodial and CowShed. Becoming a UK market leader in the supply of encapsulated Retinol.
Lipodisq® P(SMA) Polymers (SMALPs) for membrane research launched worldwide via distribution partners Sigma Aldrich (Merck).
Screened for the first time on Shop Channel Japan, selling out before the conclusion of its 3rd programme.
Production processes for custom Lipodisq® formulations successfully transferred to manufacturing facilities in Osaka to locally support Japanese market demands.
Academic groups in collaboration with Innaxon receive a Research Award at Clinam (Clinical Nanomedicine) Conference for the delivery of novel TLR4 antagonist utilising a Lipodisq® Pharma Grade formulation.
Lipodisq® distribution partnerships for Vietnamese personal care market established.
Awarded Innovate grant funding in collaboration with University of Wolverhampton to investigate novel treatments for antibiotic resistant bacterial infections of diabetic foot ulcers.
Launched custom-designed Lipodisq® Generation β formulations: Multi-Target Elixir range. Winner of multiple local beauty awards during 2018, 2019 and 2020. A collaboration that continues to yield new products for the Singaporean market.
“From Polymer Chemistry to Structural Biology: The Development of SMA and Related Amphipathic Polymers for Membrane Protein Extraction and Solubilisation” by Malvern Cosmeceutics and University of Oxford.
Distribution rights for Lipodisq® P(SMA) Polymers (SMALPs) for research purposes assigned to Polyscope Polymers NL, now part of Aurorium LLC.
protecting Generation ɑ+ Lipodisq® technology submitted: “Hydrophobically associating polymer counter ion pair complexes”. Improved Lipodisq® P(SMA) Polymers (SMALPs) technology, independent of pH conditions and with superior cation stability.
Pharmaceutical application of Generation ɑ by University of Oxford, University of Oslo and the University of Tromsø: describing in vivo bio-distribution studies of Doxorubicin loaded Lipodisq® particles for potential cancer therapy.
Lipodisq® Green range of products for personal care formulators launched in the UK in partnership with Adina Cosmetic Ingredients Ltd.
Lipodisq® distribution partnership for Korean personal care market established.
Lipodisq® technology is covered by one or more of the following patents owned by Malvern Cosmeceutics Limited:
AU 2006253886
CA 2,611,144
CN ZL200680018957.2
EP 1890675
GB 2426703
JP5142989
IN 261468
US 8623414
WO/2021/005340A1 pending
AU2007327054
CN ZL200780044148.3
GB2464393
JP6567575
JP5142989
SA2009/02939